Do analysts prefer BCTX or RNAZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, BCTX or RNAZ?

Briacell Therap is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A TransCode Therapeutics N/A N/A -$34.66M -$50.33 N/A

Is BCTX or RNAZ more profitable?

Briacell Therap's return on equity of -153.53% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% TransCode Therapeutics N/A -875.35% -50.36%

Does the media prefer BCTX or RNAZ?

In the previous week, Briacell Therap and Briacell Therap both had 1 articles in the media. Briacell Therap's average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TransCode Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GNTA or RNAZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, GNTA or RNAZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A TransCode Therapeutics N/A N/A -$34.66M -$50.33 N/A

Is GNTA or RNAZ more profitable?

Genenta Science's return on equity of 0.00% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A TransCode Therapeutics N/A -875.35% -50.36%

Do analysts recommend RNAZ or LSTA?

Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 600.93%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is RNAZ or LSTA more profitable?

Lisata Therapeutics' return on equity of -103.54% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -50.36% Lisata Therapeutics N/A -103.54% -83.08%

Does the media favor RNAZ or LSTA?

In the previous week, TransCode Therapeutics and TransCode Therapeutics both had 1 articles in the media. Lisata Therapeutics' average media sentiment score of 0.35 beat TransCode Therapeutics' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransCode Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lisata Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LITS or RNAZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LITS or RNAZ more profitable?

Lite Strategy's return on equity of -90.81% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lite Strategy N/A -90.81% -89.33% TransCode Therapeutics N/A -875.35% -50.36%

Do analysts recommend RNAZ or ESLA?

Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 895.02%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, RNAZ or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$50.33 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A

Is RNAZ or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -50.36% Estrella Immunopharma N/A N/A -397.36%

Does the media favor RNAZ or ESLA?

In the previous week, Estrella Immunopharma had 6 more articles in the media than TransCode Therapeutics. MarketBeat recorded 7 mentions for Estrella Immunopharma and 1 mentions for TransCode Therapeutics. Estrella Immunopharma's average media sentiment score of 1.10 beat TransCode Therapeutics' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransCode Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TransCode Therapeutics (RNAZ) Competitors

$8.32 -0.41 (-4.70%)

As of 01:23 PM Eastern

Compare

RNAZ vs. BCTX, GNTA, LSTA, LITS, and ESLA

Should you buy TransCode Therapeutics stock or one of its competitors? MarketBeat compares TransCode Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TransCode Therapeutics include Briacell Therap (BCTX), Genenta Science (GNTA), Lisata Therapeutics (LSTA), Lite Strategy (LITS), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry.

How does TransCode Therapeutics compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Briacell Therap is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A

15.4% of Briacell Therap shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Briacell Therap's return on equity of -153.53% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
TransCode Therapeutics	N/A	-875.35%	-50.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Briacell Therap and Briacell Therap both had 1 articles in the media. Briacell Therap's average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransCode Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Briacell Therap has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

Summary

Briacell Therap beats TransCode Therapeutics on 5 of the 8 factors compared between the two stocks.

How does TransCode Therapeutics compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.1% of Genenta Science shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genenta Science's return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
TransCode Therapeutics	N/A	-875.35%	-50.36%

In the previous week, TransCode Therapeutics had 1 more articles in the media than Genenta Science. MarketBeat recorded 1 mentions for TransCode Therapeutics and 0 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.

Company	Overall Sentiment
Genenta Science	Neutral
TransCode Therapeutics	Neutral

Genenta Science has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A

Summary

Genenta Science beats TransCode Therapeutics on 5 of the 7 factors compared between the two stocks.

How does TransCode Therapeutics compare to Lisata Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

TransCode Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Lisata Therapeutics' return on equity of -103.54% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
Lisata Therapeutics	N/A	-103.54%	-83.08%

In the previous week, TransCode Therapeutics and TransCode Therapeutics both had 1 articles in the media. Lisata Therapeutics' average media sentiment score of 0.35 beat TransCode Therapeutics' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransCode Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lisata Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 600.93%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

8.9% of Lisata Therapeutics shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lisata Therapeutics has higher revenue and earnings than TransCode Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
Lisata Therapeutics	$170K	114.68	-$16.59M	-$1.86	N/A

Summary

Lisata Therapeutics beats TransCode Therapeutics on 9 of the 12 factors compared between the two stocks.

How does TransCode Therapeutics compare to Lite Strategy?

Lite Strategy (NASDAQ:LITS) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Lite Strategy has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

52.4% of Lite Strategy shares are held by institutional investors. 1.6% of Lite Strategy shares are held by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lite Strategy's return on equity of -90.81% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-90.81%	-89.33%
TransCode Therapeutics	N/A	-875.35%	-50.36%

In the previous week, TransCode Therapeutics had 1 more articles in the media than Lite Strategy. MarketBeat recorded 1 mentions for TransCode Therapeutics and 0 mentions for Lite Strategy. Lite Strategy's average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.

Company	Overall Sentiment
Lite Strategy	Neutral
TransCode Therapeutics	Neutral

Lite Strategy has higher revenue and earnings than TransCode Therapeutics. Lite Strategy is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.54	-$15.94M	-$1.60	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A

Summary

Lite Strategy beats TransCode Therapeutics on 6 of the 10 factors compared between the two stocks.

How does TransCode Therapeutics compare to Estrella Immunopharma?

TransCode Therapeutics (NASDAQ:RNAZ) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 895.02%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Estrella Immunopharma had 6 more articles in the media than TransCode Therapeutics. MarketBeat recorded 7 mentions for Estrella Immunopharma and 1 mentions for TransCode Therapeutics. Estrella Immunopharma's average media sentiment score of 1.10 beat TransCode Therapeutics' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransCode Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Estrella Immunopharma's return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
Estrella Immunopharma	N/A	N/A	-397.36%

Estrella Immunopharma is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

0.4% of Estrella Immunopharma shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

TransCode Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Summary

Estrella Immunopharma beats TransCode Therapeutics on 10 of the 13 factors compared between the two stocks.

Get TransCode Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAZ vs. The Competition

Export

Metric	TransCode Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.93M	$3.08B	$6.80B	$12.43B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-0.17	20.12	27.03	24.19
Price / Sales	N/A	345.03	515.69	92.93
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	0.74	4.27	10.67	6.24
Net Income	-$34.66M	$65.94M	$3.59B	$331.42M
7 Day Performance	-3.03%	-1.43%	-0.60%	-1.18%
1 Month Performance	77.02%	0.21%	1.63%	-1.34%
1 Year Performance	-14.14%	17.51%	25.09%	18.73%

TransCode Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAZ TransCode Therapeutics	0.4151 of 5 stars	$8.32 -4.7%	N/A	-12.2%	$7.93M	N/A	N/A	9	News Coverage Positive News Gap Up
BCTX Briacell Therap	0.3737 of 5 stars	$3.98 +7.4%	N/A	-54.4%	$34.58M	N/A	N/A	8
GNTA Genenta Science	0.5748 of 5 stars	$1.46 +16.8%	N/A	-58.1%	$34.44M	N/A	N/A	7
LSTA Lisata Therapeutics	1.5582 of 5 stars	$3.78 +1.8%	$15.00 +297.2%	+39.5%	$34.40M	$170K	N/A	30	Gap Down
LITS Lite Strategy	0.7304 of 5 stars	$1.01 +0.8%	N/A	N/A	$34.20M	$65.30M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAZ) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransCode Therapeutics (RNAZ) Competitors

RNAZ vs. BCTX, GNTA, LSTA, LITS, and ESLA

How does TransCode Therapeutics compare to Briacell Therap?

Summary

How does TransCode Therapeutics compare to Genenta Science?

Summary

How does TransCode Therapeutics compare to Lisata Therapeutics?

Summary

How does TransCode Therapeutics compare to Lite Strategy?

Summary

How does TransCode Therapeutics compare to Estrella Immunopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ vs. The Competition

TransCode Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransCode Therapeutics (RNAZ) Competitors

RNAZ vs. BCTX, GNTA, LSTA, LITS, and ESLA

How does TransCode Therapeutics compare to Briacell Therap?

Which has higher valuation and earnings, BCTX or RNAZ?

Do institutionals & insiders have more ownership in BCTX or RNAZ?

Is BCTX or RNAZ more profitable?

Do analysts prefer BCTX or RNAZ?

Does the media prefer BCTX or RNAZ?

Which has more risk & volatility, BCTX or RNAZ?

Summary

How does TransCode Therapeutics compare to Genenta Science?

Do analysts prefer GNTA or RNAZ?

Do insiders & institutionals have more ownership in GNTA or RNAZ?

Is GNTA or RNAZ more profitable?

Does the media prefer GNTA or RNAZ?

Which has more risk and volatility, GNTA or RNAZ?

Which has preferable earnings & valuation, GNTA or RNAZ?

Summary

How does TransCode Therapeutics compare to Lisata Therapeutics?

Which has more volatility & risk, RNAZ or LSTA?

Is RNAZ or LSTA more profitable?

Does the media favor RNAZ or LSTA?

Do analysts recommend RNAZ or LSTA?

Do insiders and institutionals hold more shares of RNAZ or LSTA?

Which has better valuation and earnings, RNAZ or LSTA?

Summary

How does TransCode Therapeutics compare to Lite Strategy?

Which has more risk and volatility, LITS or RNAZ?

Do institutionals & insiders hold more shares of LITS or RNAZ?

Do analysts recommend LITS or RNAZ?

Is LITS or RNAZ more profitable?

Does the media refer more to LITS or RNAZ?

Which has stronger valuation & earnings, LITS or RNAZ?

Summary

How does TransCode Therapeutics compare to Estrella Immunopharma?

Do analysts recommend RNAZ or ESLA?

Does the media favor RNAZ or ESLA?

Is RNAZ or ESLA more profitable?

Which has stronger earnings and valuation, RNAZ or ESLA?

Do institutionals and insiders hold more shares of RNAZ or ESLA?

Which has more volatility and risk, RNAZ or ESLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ vs. The Competition

TransCode Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools